{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:06:28Z","timestamp":1783764388535,"version":"3.55.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,16]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Myasthenia gravis (MG) is an autoantibody-mediated inflammatory disease of the neuromuscular junction. Biomarkers indicating disease activity in MG are warranted. Recently, the soluble urokinase plasminogen activator receptor (suPAR) has been reported to be associated with inflammation, tissue damage, disease activity and prognosis in various diseases, including autoimmune diseases. In this study, serum suPAR levels were measured in 40\u00a0patients with anti-acetylcholine receptor antibody-positive MG and 30\u00a0controls, and their correlations with clinical variables and severity scale scores were investigated. We identified that serum suPAR levels significantly correlated with MG activities of daily living scale (Spearman's \u03c1\u00a0=\u00a00\u00b745; P\u00a0=\u00a00\u00b7004) and MG Foundation of America classification (Spearman's \u03c1\u00a0=\u00a00\u00b737; P\u00a0=\u00a00\u00b702) at serum sampling, but not with anti-acetylcholine receptor antibody titers. In conclusion, serum suPAR levels can be a candidate for a novel biomarker of disease activity in anti-acetylcholine receptor antibody-positive MG.<\/jats:p>","DOI":"10.1111\/cei.13499","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T20:23:50Z","timestamp":1595622230000},"page":"321-324","source":"Crossref","is-referenced-by-count":5,"title":["Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study"],"prefix":"10.1093","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-1863","authenticated-orcid":false,"given":"A","family":"Uzawa","sequence":"first","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"},{"name":"Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Akamine","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"},{"name":"Department of Neurology, Dowa Institute of Clinical Neuroscience, Neurology Clinic Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Himuro","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"},{"name":"Department of Neurology, Matsudo Neurology Clinic, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kuwabara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"2021121023213327500_cei13499-bib-0001","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"2021121023213327500_cei13499-bib-0002","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cca.2015.02.031","article-title":"Soluble Urokinase plasminogen activator receptor \u2013 a valuable biomarker in systemic lupus erythematosus?","volume":"444","author":"Enocsson","year":"2015","journal-title":"Clin Chim Acta"},{"key":"2021121023213327500_cei13499-bib-0003","doi-asserted-by":"crossref","first-page":"102340","DOI":"10.1016\/j.jaut.2019.102340","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus","volume":"106","author":"Enocsson","year":"2020","journal-title":"J Autoimmun"},{"key":"2021121023213327500_cei13499-bib-0004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1155\/2009\/504294","article-title":"suPAR: the molecular crystal ball","volume":"27","author":"Thun\u00f8","year":"2009","journal-title":"Dis Markers"},{"key":"2021121023213327500_cei13499-bib-0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10753-009-9152-0","article-title":"Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis","volume":"33","author":"Pliyev","year":"2010","journal-title":"Inflammation"},{"key":"2021121023213327500_cei13499-bib-0006","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.58.8.488","article-title":"Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis","volume":"58","author":"Slot","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"2021121023213327500_cei13499-bib-0007","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa1911481","article-title":"Soluble urokinase receptor and acute kidney injury","volume":"382","author":"Hayek","year":"2020","journal-title":"N Engl J Med"},{"key":"2021121023213327500_cei13499-bib-0008","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa1506362","article-title":"Soluble urokinase receptor and chronic kidney disease","volume":"373","author":"Hayek","year":"2015","journal-title":"N Engl J Med"},{"key":"2021121023213327500_cei13499-bib-0009","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"2021121023213327500_cei13499-bib-0010","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"2021121023213327500_cei13499-bib-0011","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","article-title":"Molecular intercommunication between the complement and coagulation systems","volume":"185","author":"Amara","year":"2010","journal-title":"J Immunol"},{"key":"2021121023213327500_cei13499-bib-0012","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/jnnp-2014-309232","article-title":"Serum high mobility group box 1 is upregulated in myasthenia gravis","volume":"86","author":"Uzawa","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.13499","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.13499","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.13499","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/202\/3\/321\/41635640\/cei13499.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/202\/3\/321\/41635640\/cei13499.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:24:48Z","timestamp":1641054288000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/202\/3\/321\/6403170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":12,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,8,10]]},"published-print":{"date-parts":[[2020,11,16]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13499","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,8,10]]}}}